Vascular healing in drug-eluting stents: differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation.
暂无分享,去创建一个
R. Virmani | F. Kolodgie | M. Joner | Shawn Chin Quee | R. Byrne | M. Vogeser | M. Vorpahl | S. Ballke | K. Steigerwald
[1] G. Stone,et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.
[2] J. W. Louwerenburg,et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. , 2012, Journal of the American College of Cardiology.
[3] R. Virmani,et al. Evaluation of Polymer-Based Comparator Drug-Eluting Stents Using a Rabbit Model of Iliac Artery Atherosclerosis , 2011, Circulation. Cardiovascular interventions.
[4] R. Starzyk,et al. Vascular response to a third generation everolimus-eluting stent. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[5] Saibal Kar,et al. Polymer-Free Biolimus A9–Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model , 2010, Circulation. Cardiovascular interventions.
[6] R. Virmani,et al. Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. , 2010, Biomaterials.
[7] M. Joner,et al. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. , 2009, Minerva cardioangiologica.
[8] A. Kastrati,et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. , 2009, JACC. Cardiovascular interventions.
[9] R. Virmani,et al. Drug-Eluting Stents in Preclinical Studies: Updated Consensus Recommendations for Preclinical Evaluation , 2008, Circulation. Cardiovascular interventions.
[10] R. Virmani,et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. , 2008, Journal of the American College of Cardiology.
[11] R. Virmani,et al. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. , 2007, The American journal of cardiology.
[12] P. Fitzgerald,et al. Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). , 2007, The American journal of cardiology.
[13] Michael Joner,et al. Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[14] R. Virmani,et al. Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.
[15] Michael Joner,et al. Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications , 2007, Circulation.
[16] Matthew H Samore,et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. , 2006, Journal of the American College of Cardiology.
[17] Jan J Piek,et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[18] E. Edelman,et al. Thrombosis Modulates Arterial Drug Distribution for Drug-Eluting Stents , 2005, Circulation.
[19] P. Tsao,et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. , 2004, Cardiovascular research.
[20] Giuseppe Musumeci,et al. Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.
[21] Renu Virmani,et al. Pathological Mechanisms of Fatal Late Coronary Stent Thrombosis in Humans , 2003, Circulation.
[22] Benno J. Rensing,et al. Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.
[23] R. Virmani,et al. Neointimal responses 3 months after 32P β-emitting stent placement , 2000 .
[24] R E Vlietstra,et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. , 1992, Journal of the American College of Cardiology.
[25] T. Lüscher,et al. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. , 2010, European heart journal.